GeneDx (WGS) CFO Kevin Feeley Sells 7,197 Shares

Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. (NasdaqGS:WGS), sold 7,197 shares of the company on June 16, 2026. The transaction was not part of a pre-planned trading program. Following this sale, shares were trading at $56.42.

Insider Buying and Selling at GeneDx Holdings Corp.

On the same day, Katherine Stueland, CEO of GeneDx Holdings, also sold shares, offloading 10,501 shares at an average price of $60.76. These transactions were not part of any pre-arranged selling plans.

Other Institutional Activity in GeneDx Holdings

In recent activity, Corvex Management LP increased its holdings by 169,520 shares, bringing its total to approximately 3.23 million shares valued at about $207.3 million. Westfield Capital Management Co LP made a significant addition of 350,847 shares, totaling around 1.37 million shares worth $87.9 million. Meanwhile, BlackRock, Inc. reduced its position slightly by 9,386 shares, leaving it with 1.55 million shares valued at $99.6 million.

GeneDx Holdings Corp. Stock Down 44.2%

Shares of GeneDx Holdings traded near $56.42. The company has a market cap of around $1.67 billion and a forward P/E ratio of 45.8. The stock has a 52-week low of $32.21 and a high of $170.87, with a beta of 1.971. Its 50-day moving average is $54.92, and the 200-day moving average is $99.77. The company maintains a current ratio of 3.09 and a quick ratio of 2.83, with a debt-to-equity ratio of 66.19.

Recent Earnings

GeneDx Holdings reported revenue of $442.7 million with a growth rate of 17.4%. Despite this, the company is not yet profitable, with a net margin of -17.6% and a return on equity of -30.4%. The next earnings report is scheduled for July 28, 2026.

Analysts Set New Price Targets

Analysts remain bullish on GeneDx Holdings, with firms like Canaccord Genuity and Wells Fargo maintaining a 'buy' rating and setting a price target of $75.00 as of May 5, 2026. The consensus among analysts is a 'strong buy', with a mean target price of $77.00 across nine opinions.

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is a genomics company specializing in genetic testing services. It primarily focuses on diagnostics for pediatric and rare diseases, utilizing whole exome and genome sequencing. The company is also developing an AI-based platform for sequencing analysis and clinical reporting. Headquartered in Stamford, Connecticut, GeneDx was founded in 2000 and employs approximately 1,300 people.

Bottom Line

The insider sale by CFO Kevin Feeley is part of the regular trading activities at GeneDx Holdings. Investors often watch these transactions for signals about insider confidence. GeneDx Holdings, with its focus on rare disease diagnostics and AI-driven genomics, continues to attract analyst attention, reflected in its strong buy ratings. As always, it's essential to remember that insider transactions are just one piece of the broader investment puzzle.